TickerFacts.

Scilex Holding Co (SCLX): Operating Cash Flow

Annual figures by period end, from SEC filings.

$3.82M
Year ended 2025-12-31
-$17.09M
Trailing 12 months to 2026-06-30
$19.35M2020-12-31: -$31.46M2021-12-31: -$28.66M2022-12-31: -$21.26M2023-12-31: -$20.71M2024-12-31: $19.35M2025-12-31: $3.82M$3.82M
2020-12-31 Operating Cash Flow (USD) 2025-12-31
Period endedOperating Cash FlowChange YoYSource filing
2025-12-31$3.82M-80.3%2026-04-10, From 2025-01-01
2024-12-31$19.35Mn/m2026-04-10, From 2024-01-01
2023-12-31-$20.71Mn/m2025-03-31, From 2023-01-01
2022-12-31-$21.26Mn/m2024-03-12, From 2022-01-01
2021-12-31-$28.66Mn/m2024-03-12, From 2021-01-01
2020-12-31-$31.46Mn/a2023-03-07, From 2020-01-01

Operating Cash Flow at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedOperating Cash FlowChange YoY
Scilex Holding Co (SCLX)2025-12-31$3.82M-80.3%
Precision Biosciences Inc (DTIL)2025-12-31-$65.84Mn/m
X4 Pharmaceuticals, Inc (XFOR)2025-12-31-$85.62Mn/m
C4 Therapeutics, Inc. (CCCC)2025-12-31-$98.69Mn/m
Metagenomi Therapeutics, Inc. (MGX)2025-12-31-$88.89Mn/m
Kymera Therapeutics, Inc. (KYMR)2025-12-31-$232.89Mn/m
Sangamo Therapeutics, Inc (SGMOQ)2025-12-31-$97.21Mn/m
Voyager Therapeutics, Inc. (VYGR)2025-12-31-$132.47Mn/m
Editas Medicine, Inc. (EDIT)2025-12-31-$165.24Mn/m

Compare SCLX, DTIL, XFOR, CCCC side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗